Everything you need to know about TMS for PTSD: Breaking Through Treatment Resistance — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Post-traumatic stress disorder (PTSD) affects approximately 3.5% of American adults in any given year, with dramatically higher prevalence among military veterans, first responders, and survivors of assault or accidents. Characterized by intrusive memories, hypervigilance, avoidance, negative cognitions, and emotional dysregulation, PTSD can devastate personal relationships, occupational functioning, and quality of life. While first-line treatments — including trauma-focused psychotherapy and SSRIs — are effective for many patients, a significant proportion experience persistent symptoms despite multiple treatment trials. Transcranial magnetic stimulation, both in its standard and deep forms, is generating substantial interest as a novel intervention for treatment-resistant PTSD.

What You’ll Learn

• How PTSD changes brain structure and function, particularly in the amygdala and prefrontal cortex
• The difference between standard TMS and deep TMS (H-coil) for PTSD treatment
• Why the BrainsWay deep TMS system received FDA clearance for PTSD
• What VA coverage looks like for veterans seeking TMS treatment
• What a typical TMS treatment course for PTSD involves day to day

The Neurobiology of PTSD

PTSD is not simply a psychological reaction to trauma — it is accompanied by measurable changes in brain structure and function. Neuroimaging research has identified several key abnormalities:

The amygdala is consistently hyperactive in PTSD, showing exaggerated responses to threat-related stimuli including trauma cues, neutral stimuli perceived as dangerous, and even mild stressors. This hyperactivity underlies the hypervigilance, exaggerated startle response, and emotional reactivity that characterize the disorder.

The hippocampus — critical for memory encoding and contextualization — is often reduced in volume in PTSD patients and shows impaired functioning. This may explain why trauma memories in PTSD feel so raw and unprocessed: the hippocampus fails to contextualize them as memories of past events rather than ongoing threats.

The medial prefrontal cortex (mPFC), particularly the ventromedial prefrontal cortex, is underactive in PTSD. This region normally inhibits amygdala activity through top-down regulation. When mPFC function is compromised, the prefrontal “brake” on fear responses fails, allowing the amygdala to drive symptoms unchecked.

The default mode network (DMN) is dysregulated in PTSD, contributing to intrusive re-experiencing and rumination. Abnormal DMN connectivity is thought to underlie the phenomenon of trauma flashbacks, in which patients feel as though the traumatic event is happening in the present moment.

Standard TMS for PTSD

Standard TMS for PTSD most commonly targets the right and/or left dorsolateral prefrontal cortex (dlPFC). Treatment protocols typically use:

• Low-frequency (1 Hz) right dlPFC TMS to reduce right-hemisphere hyperarousal and dampen amygdala activity
• High-frequency (10 Hz or higher) left dlPFC TMS to enhance prefrontal regulatory function
• Bilateral protocols combining both approaches

The rationale for right-sided inhibitory stimulation is to calm the hyperactive fear circuitry; the rationale for left-sided excitatory stimulation is to strengthen the prefrontal cortex’s capacity to regulate the amygdala.

Deep TMS for PTSD

Deep TMS using the H-coil represents a significant advancement in TMS treatment for PTSD. Unlike standard figure-eight coils, which primarily stimulate surface brain regions, H-coils can reach deeper structures including the ACC, insula, and medial temporal regions — many of which are directly implicated in PTSD pathophysiology.

The BrainsWay deep TMS system has been the subject of extensive PTSD research. In 2020, the company announced the publication of a large randomized controlled trial demonstrating significant PTSD symptom reduction with deep TMS compared to sham treatment. The trial used a protocol targeting the mPFC and ACC bilaterally — regions that are difficult or impossible to reach with standard coils.

What the Evidence Shows

A substantial body of research now supports the use of TMS for PTSD:

A 2020 randomized sham-controlled trial published in Neuropsychopharmacology found that patients receiving deep TMS to the mPFC/ACC showed significantly greater improvements in PTSD symptom severity (measured by the Clinician-Administered PTSD Scale, CAPS-5) compared to sham treatment. Response rates were approximately 40% for active TMS versus 20% for sham.

A meta-analysis published in Translational Psychiatry reviewed 11 TMS trials for PTSD and concluded that TMS produces statistically significant and clinically meaningful reductions in PTSD symptoms. The analysis found that effect sizes were larger for deep TMS than for standard TMS, and that bilateral and right-sided protocols showed particular promise.

Importantly, TMS for PTSD has been shown to reduce amygdala reactivity and increase mPFC activation after treatment — the precise neurobiological changes that would be expected if the treatment were addressing the underlying pathophysiology rather than merely suppressing symptoms.

FDA Status and VA Coverage

As of 2026, the BrainsWay deep TMS system holds FDA clearance for treating PTSD in adults who have failed to respond to at least one course of medication. This is a significant milestone, as it establishes TMS as an officially recognized treatment option for PTSD within the United States regulatory framework.

This FDA clearance also has implications for Veterans Affairs (VA) coverage. The VA system has been actively exploring neuromodulation treatments for PTSD in veterans, and several VA medical centers now offer TMS as a treatment option. Coverage varies by facility, but veterans who meet criteria (typically, failure of at least one adequate medication trial) may be eligible for TMS treatment through the VA.

Private insurance coverage for TMS for PTSD is more variable. Because TMS is FDA-cleared for PTSD, some insurers will cover it; others may still consider it investigational for this indication. Patients should check with their insurance provider and their treatment team to understand coverage options.

What Patients Can Expect

A typical TMS course for PTSD involves daily sessions (five days per week) for four to six weeks, with each session lasting approximately 20 to 37 minutes. Treatment is administered in an outpatient setting without anesthesia.

For veterans and first responders with severe PTSD, the maintenance and booster session protocol is particularly important. Many clinicians recommend periodic “booster” sessions after the initial treatment course to sustain improvements, given that PTSD is often a chronic condition with a relapsing course.

A Comprehensive Approach

TMS should not be viewed as a standalone cure for PTSD. The most effective treatment programs integrate TMS with trauma-focused psychotherapy — particularly EMDR (eye movement desensitization and reprocessing) and prolonged exposure therapy — as well as psychiatric medication management when appropriate.

For veterans, active-duty service members, and civilian trauma survivors who have exhausted conventional treatment options, TMS represents a meaningful new pathway to symptom reduction and functional recovery.